Biotech

Apricus Biosciences APRI Stock News

Apricus Biosciences Inc (NASDAQ: APRI)

Apricus Biosciences is having an incredibly hard day in the market, and for good reason. The company has been in the midst of a Phase 2b proof-of-concept study that investors found out today missed its primary endpoint. Today, we’ll talk about the details of the study, what we saw in the market as a result, and what we can expect to see from APRI moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

APRI Misses Primary Endpoint

As mentioned above, Apricus Biosciences has been in the midst of a Phase 2b study. The proof-of-concept study was looking into fispemifene as a treatment for men with secondary hypogonadism and sexual dysfunction. Ultimately, the goal of the study was to prove that not only was fispemifene safe and tolerable, the treatment would improve sexual function in men with hypogonadism. According to the announcement made by APRI today, the treatment did demonstrate statistically significant improvements in total, percent free and percent bioavailable testosterone compared to a placebo. However, the magnitude of the increase was not sufficient to achieve statistical significance for either the erectile function primary endpoint or low libido secondary endpoint.

APRI also announced that the treatment was generally well tolerated. According to the results of the study, there were no new or significant safety issues that arose as a result of the treatment. Apricus announced that there were no serious adverse events experienced on fispemifene and that there were few discontinuations. Nonetheless, the study did miss its primary and secondary endpoints, causing concern for investors. In a statement, Richard Pascoe, CEO at APRI had the following to offer:

We are obviously disappointed with these results… As a consequence of these results, we will discontinue all development of fispemifene in symptomatic secondary hypogonadism, and focus our resources on our other homegrown pipeline assets. Specifically, we will focus on growing ex-U.S. Vitaros revenues, seeking U.S. Vitaros approval in 2017, and advancing RayVa with a Phase 2 clinical development program. We believe that focusing on these higher return assets, along with streamlining the organization and reducing our operating expenses, is in the best interest of shareholders.”

How The Market Reacted To The News

One of the first things that we learn as investors is the fact that the news moves the market. Any time there is positive news revolving around a publicly-traded company, we can expect to see gains in the value of the stock associated with that company. However, the news revolving around APRI is anything but positive, and when we see negative news, we can expect negative results. That’s exactly what we’re seeing from the stock today. Currently (9:44), APRI is trading at $0.62 per share after a loss of $0.73 per share or 54% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from Apricus Biosciences. There’s no denying that after the poor trial results and abandonment of a treatment, the company has a rough road ahead of them. However, I am impressed by the alternative plan the company has set forth. While I do believe that the company will make it over this hurdle, it’s going to take some time. So, now definitely wouldn’t be the time to get involved in this stock.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think APRI is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of The Blue Diamond Gallery]

Cytori CYTX Stock News

Cytori Therapeutics Inc (NASDAQ: CYTX)

Cytori Therapeutics is having a strong day in the market today, and for a very good reason. It was announced early this morning that the company received a very important notice from the European Medicines Agency, also known as EMA. Today we’ll talk about the news CYTX received from the EMA, what it means for the company, how the stock reacted to the news, and what we can expect to see from CYTX moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

Cytori Is Granted SME Status

Early this morning, it was announced that CYTX has received word from the European Medicines Agency that the Micro, Small and Medium-sized Enterprise office has granted SME status to the company. This is incredibly important because this status allows CYTX to participate in incredible financial incentives, fee waivers, and fee reductions for some of the EMA’s regulatory filings. Ultimately the SME status was created as an initiative to promote innovation and development of new medical products by smaller companies. In statement, Tiago Girao, CFO at CYTX had the following to say:

Our SME status could not have come at a more opportune time as we prepare to engage with the EMA for discussions regarding our lead development program for impaired hand function from scleroderma. Incentives provided, including reductions in regulatory fees will result in significant savings, which will help to bolster our cash management activities… More importantly, Cytori is dedicated to commercializing a treatment for scleroderma patients. This SME designation will help us drive towards this objective.”

How The Market Reacted To The News

When it comes to investing, one of the first things we learn is that the news moves the market. Any time there is positive news with regard to a publicly-traded company, we can expect to see gains in the value of the stock associated with that company. Adversely, when there is negative news released with regard to a publicly-traded company, we can expect to see declines. In the case of CYTX, the news released this morning was overwhelmingly positive. So naturally, we’re seeing gains in the value of the stock today. Currently (10:47), CYTX is trading at $0.19 per share after a gain of 1.98% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Cytori. First and foremost, the news that was released today was overwhelmingly positive news that’s likely to lead to gains for the stock moving forward considering the amount of savings the company will realize as a result of the discounts associated with the new status in Europe. Outside of that however, I have been bullish on CYTX for some time now. In fact, for several months, I’ve been watching their movements with regard to working toward a treatment for scleroderma. Overall, the news released by the company with regard to their developments has been incredibly positive. Considering this, I’m expecting that, in due time, the company will come up with a positive treatment, leading to profitability. All in all, I’m expecting to see gains in the long run.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think CYTX is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of YouTube]

Valeant Pharmaceuticals VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant Pharmaceuticals has been struggling for quite some time, and for an incredibly good reason. The company has had several accounting errors and had an iffy-at-best relationship with an underground pharmacy known as Philidor. Soon, Citron started to call VRX the Enron of the biotechnology industry as it brought to light the issues with the company. Investors held onto the statements and VRX started to fall dramatically. When this all started, the stock was trading at over $100 per share. Now it sits around $30 per share. Nonetheless, Valeant recently closed over 7% higher as the result of a big announcement. Can it go higher? Today, we’ll talk about the announcement that was made, what we’re seeing from Valeant Pharmaceuticals in the market today, and what we can expect to see moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

VRX Releases Information That Excites Investors

In any case, the CEO of the company is the leader, and therefore, the person to blame when something goes wrong. So, when we see something bad happen with regard to a publicly-traded company, it’s common practice that the CEO may step down. That’s exactly what we’re seeing from VRX. On Monday, it was announced that the company would be hunting for a new CEO as the current CEO will soon be stepping down. He will continue to hold his position at Valeant until a new CEO is found. On top of the CEO change, VRX made changes to its board of directors and offered an update with regard to accounting and financial reporting issues. Yesterday, the company came out and accused the former CFO of VRX of “improper conduct” that led to the misstatements in financial results. In fact, in a press release on Monday, Valeant had the following to say about its former CFO:

The improper conduct of the company’s former Chief Financial Officer and former Corporate Controller, which resulted in the provision of incorrect information to the Committee and the company’s auditors, contributed to the misstatement of results. In addition, as part of this assessment of internal control over financial reporting, the company has determined that the tone at the top of the organization and the performance-based environment at the company, where challenging targets were set and achieving those targets was a key performance expectation, may have been contributing factors resulting in the company’s improper revenue recognition.”

What We’re Seeing From VRX Today

While we are still well in the beginning of the day, things are looking to be shaping up to be a great Wednesday for Valeant Pharmaceuticals. Currently (9:42), the stock is trading at $32.70 per share after a gain of $0.79 per share or 2.48% thus far today.

What We Can Expect To See Moving Forward

When it comes to VRX, it is my belief that the struggles are over for the most part. The reality is that VRX made some very big mistakes, and ultimately, the company is paying for those mistakes. However, since the issues have come to light, Valeant has made changes with regard to management, has re-established realistic accounting figures, and has even signed a contract with Walgreens for the sale of their treatments. All in all, things seem to be heading back in the right direction and I’m expecting to see gains in the long run as a result.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think VRX is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

MannKind is an absolutely incredible company. When we talk about MNKD, we’re talking about a company that has been able to turn an injection only medication into a medication that can be inhaled. Unfortunately however, the company has received a bit of a bad reputation in the stock market. Over the past several months, we’ve watched as the stock has fallen like a brick from the Empire State Building. However, more recently, we’ve been seeing a bit of a recovery. Throughout this entire time, I have maintained a bullish opinion on the stock. I’ve received emails from the bulls and the bears telling me how much they agree or how much they disagree. Nonetheless, my opinion on the stock is here to stay, and for good reason. Today, I’ll explain why even after the massive declines we’ve seen on MNKD, I’m still a bull.

Trade smarter and make more money with Tradespoon!

Understanding Why MannKind Fell So Far So Fast

In late 2014, MNKD finally received notice from the United States Food and Drug Administration that Afrezza, its inhaled insulin, had been approved for the treatment of diabetes. At that time, investors cheered, and the stock climbed. After all, there had been no other product like it in the past. So naturally, investors got excited.

After the approval of Afrezza, MannKind contracted the commercialization of the treatment to a company known as Sanofi. Ultimately, it was Sanofi’s job to ensure that Afrezza was a success. However, for the year the contract was open, SNY did nothing more than drag its feet. As a result, Afrezza didn’t reach the sales potential that everyone thought it would, sending MNKD down in the market.

Why I’m Bullish On MNKD

Since the issues with Sanofi, investors have taken a very bearish stance when it comes to MNKD. Unfortunately, many simply don’t believe that Afrezza will sell. While I do, that’s not the only reason I maintain a bullish opinion on MNKD. Here’s why I love this stock:

  • Afrezza Plans – In early January, it was announced that the relationship between MannKind and Sanofi was coming to an end. As a result, the commercialization rights to Afrezza would transfer back to MNKD, giving them the ability to properly market Afrezza. While the transfer isn’t quite complete at the moment, MNKD has announced a key plan that I believe will send Afrezza sales through the roof. The company has worked on an agreement with an independent entity known as Specialized Diabetes Care Centers. These centers have agreed to treat diabetes in real time with Afrezza, which will cause Afrezza sales to climb.
  • New Management – Alfred Mann was an absolutely amazing man. However, in his old age, he had a hard time properly managing MNKD. Today, MannKind is under new management, and the management team is a team of geniuses. We’ve already seen some of their ideas come to fruition and I’m incredibly excited to see further moves.
  • Technosphere – While Afrezza is MannKind’s only approved medication, it’s not their only product. In fact, MNKD is the creator of Technosphere – the technology that allows insulin and other injection only treatments to be inhaled. In fact, MNKD has already contracted the development of new treatments using technosphere out, and this is likely to lead to long-run gains.
  • Finances – While finances are a concern to many investors, I have to say that I’m really not too concerned. Early in the year, MNKD said that it had enough money to get it comfortably into the second half of the year, and could possibly stretch that money further. The marketing plans they have with regard to Afrezza will lift sales and give them even more funding to work with. On top of that, I’m expecting more Technosphere agreements down the line that will give MannKind operating funds.

The Bottom Line

The bottom line here is that I can understand the bearishness with regard to MNKD. However, the company is getting things back into place to move forward. The reality is that companies go through hurdles, and MNKD is going to easily clear this one.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think MNKD is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of YouTube]

Biotech Stock News

GW Pharmaceuticals (NASDAQ:GWPH)

On March 14, 2016 shares of GW Pharmaceutical were up 124% after the company announced that it had obtained positive phase 3 results for its drug, known as Epidiolex. The drug was able to meet the primary endpoint of the study, which was a reduction of seizures compared to the placebo. The drug was statistically significant because it had obtained a p-value of p = .01. What should be taken away here is that any p-value below .01 should be taken as a positive.

Trade smarter and make more money with Tradespoon!

The patients recruited are those with a rare-form of epilepsy known as Dravet Syndrome. Patients with this disease experience seizure events with certain triggers. Such triggers are extremely hot temperatures or getting a fever. It is devastating to go through seizures every time because of these triggers, and a drug that can help reduce seizures is a welcomed component. After all, there are no FDA approved drugs to treat Dravet Syndrome.

There were a total of 120 patients who were randomized into two different dose groups. One group took 20 mg/kg/day of Epidiolex, and the other group took the placebo compound instead. The trial results were not only positive, but the Epidiolex treatment was safe and well tolerated in all patients. The next action is for GW Pharmaceuticals to have a pre-NDA meeting with the FDA to determine possible marketing approval for Epidioldex in patients with Dravet Syndrome.

Celator Pharmaceuticals (NASDAQ:CPXX)

In after-hours trading on March 14, 2016 shares of Celator Pharmaceuticals rocketed 300% after the company announced positive phase 3 results in patients with high-risk acute Myeloid Leukemia — AML. The company’s drug is known as VYXEOS and was being compared in the trial against the current standard of care regimens cytarabine and daunorubicin. Celator’s drug met on the primary endpoint of the study which was improved overall survival.

The median survival in the VYEXOS group was 9.56 months compared to 5.95 months in the placebo group. This means that VYXEOS reduced the risk of death in patients with high-risk AML by 31%. The company now expects that it will file an NDA to the FDA later in the year for marketing approval of the drug. It also states that it will file a Marketing Authorization Application — MAA – by the first quarter of 2017 for the same indication.

The drug was safe and well tolerated in all patients that were tested. There are some minor grade 3 adverse events in the VYXEOS group, which is similar to the current standard of care drugs. Despite these minor adverse events VYXEOS was able to improve overall survival for these patients, which is no small feat. Considering the market cap of the company is still low, there is a possibility that it could run once the NDA is filed.

Vitae Pharmaceuticals (NASDAQ:VTAE)

On Wednesday March 16, 2016 shares of Vitae Pharmaceuticals were up by 50% after the company announced positive phase 2a results in patients with moderate-to-severe psorasis. The company’s drug used to treat these patients with psoriasis is known as VTP-43742. Psoriasis is a disease of the skin characterized by scaly patches that itch. The results were not only great but both dose groups of VTP-43742 were positive relative to placebo.

The higher dose group of 700 mg achieved a 30% reduction of PASI score compared to placebo, and the 350 mg dose group achieved a 24% reduction in PASI compared to placebo. PASI is an index that measures the amount of area affected by psoriasis.

Don’t waste your time! Click here to find winning trades in minutes!

Vitae’s next step is to start another phase 2 trial that will test VTP-43742 over a 16-week period to confirm initial efficacy. If the company can replicate the same results in this extended trial, then it will see a higher share price in the coming year. Although, on the other hand if it doesn’t meet the primary endpoint for positive efficacy it could see quite a huge tumble. Investors should only risk what they can afford to lose, because it will still be a risky bet.

[Image Courtesy of Public Domain Pictures]

Sarepta Therapeutics SRPT Stock News

Sarepta Therapeutics Inc (NASDAQ: SRPT)

Sarepta Therapeutics is an incredibly strong stock in the biotechnology space. However, it seems as though the stock is going to get stronger, and it’s going to happen soon. I’m not quite sure what’s up their sleeve, but insider trading shows that something big is likely to happen as SRPT. Today, we’ll talk about why it’s important to watch insider trading, what we’re seeing from SRPT, and what we can expect to see moving forward. So, let’s get right to it!

Trade smarter and make more money with Tradespoon!

Why It’s Important To Watch Insider Trading

As investors, we really don’t have very much information available to us. Sure, we can watch technical data and focus on the fundamental data we know, but the truth is, most fundamentals are outdated by the time we have access to them. Nonetheless, there is one clue that often leads to big gains (or big declines); that clue is insider trading. The bottom line is that no one knows more about a publicly-traded company than those on the inside. When they start to sell shares in the company for which they are insiders, we can expect to see declines. However, when they start to buy shares, we can expect that something big is just around the corner, and SRPT insiders are buying shares!

We’re Seeing Quite A Bit Of Insider Activity In Sarepta Therapeutics

Over the past week or so, we’ve seen quite a bit of positive insider activity at SRPT. In fact, over this short period of time, three directors at the company have made the decision to purchase shares. Between the three insiders, a total of 154,500 shares were purchased. The prices on these shares ranged from $14.54 per share to $16.54 per share, placing the total cost to the insiders at approximately $2.5 million. When one insider purchases shares, we expect to see something good happen. However, in the case of SRPT, three insiders started loading up on shares at the same time. While I’m not sure what they see coming around the corner, there’s got to be a reason these three insiders jumped in on $2.5 million in shares of the company.

What We Can Expect To See Moving Forward

As mentioned above, I’m in the dark just like you when it comes to what’s coming. The truth is that I have no crystal ball, nor do I have any other way to look into the future. However, I do know that when we start to see big insider buys, those insiders are buying for a reason. In the case of SRPT, I don’t see this any different. The insiders made educated decisions to purchase shares. Why? I have no idea, but they did!

With that said, I’m expecting to see something big from the company relatively soon. Maybe they’ve reached a big time medical breakthrough, maybe they are expecting to move forward with a new clinical study, maybe they just have great financial data to report. Nonteheless, something is coming so we need to be watching closely. This could open the door to incredible trading opportunities.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think SRPT is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Horizon Pharma HZNP Stock News

Horizon Pharma PLC (NASDAQ: HZNP)

Horizon Pharma is having an incredible day in the market today, and for a very good reason. The company has received a Notice of Compliance for RAVICTI in Canada. Today, we’ll talk about the details of the NOC, how the market is reacting to the news, and what we can expect to see from HZNP moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

HZNP Receives Notice Of Compiance From Health Canada

Health Canada is equivalent to the Food and Drug Administration in Canada, and they’ve sent very good news to Horizon Pharma. It was announced early this morning that HZNP has received a Notice of Compliance from Health Canada for RAVICTI Oral Liquid for use as an adjunctive therapy for chronic management of Urea Cycle Disorders in adult and pediatric patients two years or older. According to recent data, UCDs currently impact 200 people in Canada. These patients often experience episodes where they experience symptoms from the ammonia in their blood being excessively high, leading to crisis. In a statement Timothy P. Walbert, HZNP Chairman, President and CEO, had the following to say:

The approval of Ravicti in Canada is a significant milestone for Horizon Pharma as it continues to expand the accessibility of important medicines to patients with unmet treatment needs… I commend Health Canada for acknowledging the importance of this innovative medicine and the company intends to rapidly pursue funding and reimbursement. Horizon will soon be filing clinical and cost effectiveness submissions to the respective health technology assessment agencies in Canada and engaging with public and private drug plans to ensure that patients with Urea Cycle Disorders who may benefit from treatment are able to access RAVICTI as quickly as possible.”

How The Market Reacted To The News

As investors, we have learned that the news moves the market. Any time there is positive news released with regard to a publicly-traded company, we can expect to see gains in the stock. Adversely, negative news will cause declines. Given the fact that HZNP has received approval for an important treatment in Canada, the positive news is leading to an overwhelmingly positive reaction in the market. Currently (11:17), the stock is trading at $14.96 per share after a gain of $0.94 per share, or 6.70%, thus far today.

What We Can Expect To See Moving Forward

I’ve been following HZNP for quite some time now, and I have to say that I’ve been a bull on the stock the whole way through. This has not changed in the least. In fact, the news today makes me even more excited to see the growth that Horizon Pharma is likely to accomplish moving forward. The reality here is that Canada approving RAVICTI further validates the fact that this is an effective treatment for Urea Cycle Disorders and will likely lead to approval from other regulatory agencies around the world relatively soon. When it comes to HZNP, we’re talking about a company that has an incredible pipeline, great products that have already been approved, and an amazing management team. Perhaps more importantly, HZNP has a solid plan for growth moving forward. All in all, I’m expecting to see incredible gains out of the stock.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think HZNP is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Pixabay]

Valeant Pharmaceuticals VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant Pharmaceuticals has had an incredibly hard time in the market as of late, and for good reason. After the company’s relationship with an underground pharmacy known as Philidor came to light in the media, many questions were raised. As a result, the company had to cease business with the pharmacy which happened to be its biggest customer. Soon sales fell and further questions came up about the stock. Nonetheless, VRX is up big in the market today after big changes were announced with regard to the management of the company. Here’s what’s happening…

Trade smarter and make more money with Tradespoon!

Bill Ackman Will Be On The Board Of Directors

It was announced earlier this morning that Bill Ackman will be added to the board of directors at VRX. After all of the hardship the company has faced, they needed to bring on a high profile expert that would help the business grow. Now, I’ve followed Ackman for quite some time, and I have to say I’m not a huge fan of him as much as I know of him on a personal level. However, when it comes to business, the guy is an absolute genius! So, taking that into account, it’s overwhelmingly clear why investors are so happy that Ackman is being brought onto the board of directors.

J. Michael Pearson Will Be Stepping Down

J. Michael Pearson has served as the CEO of VRX for quite some time now. However, following the issues the company has faced as of late, he will be stepping down. While Valeant Pharmaceuticals searches for a successor to Pearson, he will maintain his role as CEO. In a statement, Pearson had the following to say:

It’s been a privilege to lead Valeant for the past eight years… While I regret the controversies that have adversely impacted our business over the past several months, I know that Valeant is a strong and resilient company, and I am committed to doing everything I can to ensure a smooth transition to new leadership.”

Robert Ingram, Chairman of the Board, also had a bit to say about the transition to a new CEO. Here’s what he had to say:

While the past few months have been difficult, Valeant has a collection of leading brands, valuable franchises and great people, and I am confident that the company will be able to rebuild its reputation and thrive under new leadership. We thank Mike for his dedicated service to Valeant and for agreeing to stay on until we conclude our search. As a colleague and a friend he will be missed, and we wish him the best for the future.”

How The Market Reacted To The News

As investors, we know that any time there is positive news with regard to a publicly-traded company, we can expect to see gains in the value of the company. While management changes aren’t always positive news, the fact that Bill Ackman will be taking a seat on the board at VRX and that the company is looking for a new CEO is definitely positive news. As a result, we’re seeing strong growth in the value of the stock today. Currently (10:45), VRX is trading at $30.40 per share after a gain of $3.42 per share or 12.68% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly positive view of what we can expect to see from VRX. The reality is that Valeant Pharmaceuticals has an incredible growth story, one that has required them to make it over hurdles in the past. Every time, they have done just fine. Now, with the new leadership coming on board, things are looking better than ever. Sure, VRX is in a rough patch at the moment, but the sun always shines after a rainy day.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think VRX is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

MannKind is having a rough day in the market today, and for good reason. The company reported earnings after the closing bell yesterday as expected. Unfortunately, the report missed all expectations, putting fear in the minds of investors and leading to big declines on the stock. Today, we’ll talk about what we saw from the earnings report, how investors reacted to the news, and what we can expect to see from MNKD moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

MNKD Misses Earnings Expectations

As mentioned above, MannKind reported its earnings for the fourth quarter following the closing bell yesterday. Unfortunately, the report was overwhelmingly negative. The company reported absolute zero in terms of revenue, while posting a wider loss than expected. In the quarter, analysts expected that MNKD would generate a loss of $0.05 per share. However, the company actually reported a loss of $0.66 per share. Not only did this widely miss analyst expectations, it shows a massive decline year over year. In the same quarter of 2014, the company reported a loss of only $0.09 per share. In a statement, Matthew Pfeffer, CEO of MNKD had the following to offer:

Our financial results for 2015 were not what we expected going into the year, but we are looking forward to the next twelve months with optimism and great excitement… Afrezza will soon be back under our control and we are all energized about the opportunity to launch a lean, focused commercial effort that highlights the differentiating qualities of our lead product.”

How The Market Reacted To The News

As investors, we know that the news moves the market. Any time we see positive news with regard to a publicly-traded company, we can expect to see gains in the value of the stock associated with that company. Adversely, when there’s negative news, we can expect to see declines. So naturally, we’re seeing declines on the value of MNKD today. The bottom line is that the overwhelmingly poor earnings report is creating a point of concern for investors, and concerned investors cause stocks to drop. Currently (11:22), MNKD is trading at $1.23 per share after a loss of $0.16 per share or 11.87% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from MNKD. In the short run, chances are that the stock is going to continue on the downward path as investors continue to show their disappointment with regard to earnings. However, in the long run, I still maintain a relatively bullish opinion. My opinion on MannKind is wholly centered around the company’s lead product, Afrezza. When I first heard of Afrezza, even in trial stages, I was incredibly interested in what I was hearing. I have diabetic family members, and I can’t think of one that likes injecting themselves with insulin. Not to mention, there are many benefits to an inhaled insulin like offering it to those with a fear of needles, children, and those who work in areas without access to a public restroom. The reality is that MNKD should have no problem commercializing this treatment. While Sanofi did drag their feet and delay commercialization, they didn’t kill the chances for MNKD to be successful with this revolutionary treatment.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think MNKD is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Pixabay]

Orexigen OREX Stock News

Orexigen Therapeutics, Inc. (NASDAQ: OREX)

Orexigen Therapeutics is having an interesting day in the market today after announcing big changes with regard to CONTRAVE. Today, we’ll talk about the changes the company is making, what we’re seeing in the market as a result, and what we can expect to see from OREX moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

OREX Cancels Agreement With Takeda Pharmaceuticals

For quite a while, Orexigen and Takeda Pharmaceuticals have been in the midst of a collaboration agreement surrounding CONTRAVE. It was announced today that the companies have made the decision to terminate the collaboration agreement surrounding the weight management drug. OREX believes that the cancellation of the agreement will greatly increase long-term potential with regard to corporate profitablility as well as open up multiple paths for greater value creation for its shareholders.

OREX Quickly Rebounds With Valeant Pharmaceuticals

Shortly after it was announced that Orexigen would be cancelling its agreement with Takeda, another big announcement was made. OREX announced that it has entered into a commercialization agreement with Valeant Pharmaceuticals (NYSE: VRX) under which VRX will retain commercialization rights to CONTRAVE in the United States as well as in Mysimba in Central and Eastern Europe.

How The Market Reacted To The News

As investors, we know that the news moves the market. Any time there is positive news with regard to a publicly-traded company, we can expect to see gains in the value of the stock associated with that company. Adversely, any time there is negative news with regard to a publicly-traded company, we can expect to see declines. In after-hours trading, OREX was having a great time. However, following the release of the news, we saw massive declines on the stock as investors showed their disapproval of the movement. Currently (10:54), OREX is trading at $0.66 per share after a loss of $0.04 per share or 5.67% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from OREX. In the short term, things aren’t looking good. It’s clear that investors are concerned with Orexigen’s decision to sign the agreement with Valeant Pharmaceuticals. The truth is, Valeant Pharmaceuticals has been thrown into the fire in recent months following the uncovering of its relationship with the underground pharmacy, Philidor. Since then, the company has been struggling to lift prescription numbers, eventually signing an agreement with Walgreens for the sale of its treatments. However, the numbers still aren’t perfect. At the moment, OREX investors are worried that the agreement signed with VRX will lead to declining sales of CONTRAVE. However, I don’t believe that this will be the case. Believe it or not, I have quite a bit of faith in VRX to do the right thing and really pick things up here. With that said, I’m expecting to see strong gains in Orexigen in the long term as a result of this agreement.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think OREX is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of YouTube]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7802
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...